Angiopoietin 2 inhibitor is a class of pharmaceutical agents designed to target the Angiopoietin 2 (Ang-2) protein, involved in regulating angiogenesis and vascular permeability. By inhibiting Ang-2, these drugs aim to modulate blood vessel formation and integrity. They find application in various disease indications, including cancer, ocular diseases such as age-related macular degeneration (AMD), and inflammatory disorders, where pathological angiogenesis plays a significant role. According to WHO, cancer is a major public health concern in both Europe and the USA, with approximately 4 million new cases diagnosed annually in each region. Age-related macular degeneration (AMD) affects over 20 million people aged 50 and above in Europe, while the USA has more than 11 million reported cases. Additionally, inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease have a substantial burden, affecting millions of individuals in both regions.
The growth drivers of the Angiopoietin 2 inhibitor market include the rising incidence of cancer and ocular diseases, increased research and development efforts by pharmaceutical companies, and expanding applications of Ang-2 inhibitors in inflammatory disorders. Companies such as Amgen, Bayer, Regeneron, Pfizer, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Innovent Biologics, Novartis, Roche, Takeda. are pharmaceutical companies operating in the healthcare industry. cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Pfizer is currently conducting a clinical trial of the drug PF-4856884 for the treatment of adenocarcinoma.
Key Developments
- In May 2023, the US FDA accepted sBLA for Roche’s Faricimab for Retinal edema for review.
- In March 2022, Boehringer Ingelheim completed a phase I trial of BI 836880 for Solid tumors in Japan.
Approved Angiopoietin 2 Inhibitor molecules
- Vabysmo (faricimab-svoa)
Angiopoietin 2 Inhibitor Pipeline Molecules
- Trebananib (AMG 386)
- Olodanrigan (EMA401)
- BI 836880
- PF-4856884
- MEDI-3617
- Zansecimab (LY3127804)
- AMG 780
- CVX-241
- IBI324
- L1-10
Clinical Activity and Development of Angiopoietin 2 Inhibitor
In the Angiopoietin 2 Inhibitor space, there are very few companies conducting more than 100 clinical trials in this category of drugs. For instance,
- In Oct 2022, Boehringer Ingelheim initiated a phase I/II trial of BI 836880 for wet age-related macular degeneration USA
- In Dec 2019, Amgen completed a phase II trial of Trebananib in Ovarian cancer, Fallopian tube cancer and Peritoneal cancer in the US, Canada, Australia, Belgium and India
|
Product Name |
Total Studies |
|
Trebananib (AMG 386) |
34 |
|
Olodanrigan (EMA401) |
16 |
|
BI 836880 |
8 |
|
PF-4856884 |
4 |
Target Indication Analysis of Angiopoietin 2 Inhibitor
Angiopoietin 2 (Ang-2) inhibitors are promising therapeutic agents aimed at treating various diseases by targeting the Ang-2 protein, which plays a crucial role in angiogenesis and vascular remodeling. These inhibitors aim to disrupt the Ang-2/Tie2 signaling pathway, which regulates blood vessel formation and permeability. By inhibiting Ang-2, these drugs have potential applications in conditions like cancer, ocular diseases (e.g., age-related macular degeneration), and inflammatory disorders. By modulating the angiogenic process, Ang-2 inhibitors may offer novel treatment options to control pathological angiogenesis and restore vascular homeostasis, thereby potentially improving patient outcomes in diverse clinical settings.
Angiopoietin 2 Inhibitor Market
The global Angiopoietin 2 Inhibitor market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The US Angiopoietin 2 inhibitor market has witnessed steady growth due to its potential applications in diverse therapeutic areas. With a robust healthcare infrastructure, increasing R&D investments, and a high prevalence of diseases like cancer and ocular disorders, the demand for Ang-2 inhibitors remains strong. Key pharmaceutical companies, including Amgen, Regeneron, and Pfizer, are actively engaged in clinical trials and product development, further driving market expansion. However, stringent regulatory approvals and the presence of well-established therapies pose challenges to market penetration. The Angiopoietin 2 inhibitor market is propelled by several growth drivers. First, the rising incidence of cancer and age-related macular degeneration (AMD) fuels the demand for novel treatments that target angiogenesis. Second, the growing understanding of Ang-2's role in vascular remodeling and inflammatory diseases creates opportunities for expanding indications. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for Angiopoietin 2 Inhibitors. These countries are increasingly adopting Angiopoietin 2 Inhibitors due to their efficacy and potential to improve patient outcomes. On the other hand, the Angiopoietin 2 Inhibitor market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the Angiopoietin 2 Inhibitor market.
Latin America
Europe
Asia Pacific
Middle East
North America
Frequently Asked Questions
Angiopoietin 2 inhibitors drugs are used in the management of cancer, ocular diseases (e.g., age-related macular degeneration), and inflammatory disorders.
The Angiopoietin 2 inhibitor market is propelled by several growth drivers. First, the rising incidence of cancer and age-related macular degeneration (AMD) fuels the demand for novel treatments that target angiogenesis. Second, the growing understanding of Ang-2's role in vascular remodeling and inflammatory diseases creates opportunities for expanding indications.
The major players in this space are Amgen, Bayer, Regeneron, Pfizer, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Innovent Biologics, Novartis, Roche, Takeda. are pharmaceutical companies operating in the healthcare industry.
The restraints of the Angiopoietin 2 inhibitor market include limited clinical evidence supporting their efficacy in certain indications, which may hinder their adoption in some therapeutic areas. Additionally, competition from well-established therapies and the potential for adverse effects could also pose challenges to the market's growth.
Key Features of the Report
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- Amgen
- Bayer
- Regeneron
- Pfizer
- AstraZeneca
- Boehringer Ingelheim
- Eli Lilly
- Innovent Biologics
- Novartis
- Roche
- Takeda